Targeted nanoparticles for treating resistant breast cancer
Official title: Formulation of a targeted nanoparticle system for the treatment of chemoresistant breast cancer
Funded at Xavier University of Louisiana · NIH-10867375 · Data updated 2026-11-12
This study is testing a new way to deliver the chemotherapy drug doxorubicin directly to hard-to-treat breast cancer cells, hoping to make the treatment work better and cause fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | September 1, 2021 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $112,500 |
| NIH project number | 5SC3GM142001-04 |
| Project ID | NIH-10867375 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Her-2+ breast cancer who have shown resistance to standard chemotherapy treatments.
✕Less likely to help
Patients with non-breast cancer types or those who do not have chemoresistant breast cancer may not benefit from this research.
What this research studies
This research focuses on developing a specialized nanoparticle system designed to deliver the chemotherapy drug doxorubicin directly to chemoresistant breast cancer cells. By using an aptamer-labeled liposomal delivery method, the goal is to enhance the effectiveness of doxorubicin while reducing its harmful side effects on healthy tissues. The approach aims to overcome the challenges posed by multidrug resistance in cancer cells, which often limits the success of traditional chemotherapy. Patients may benefit from a more effective treatment option that minimizes toxicity and improves outcomes.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with chemoresistant breast cancer.
How similar studies have gone: Other research has shown promise in using targeted nanoparticle systems for cancer treatment, indicating a potential for success with this novel approach.
Where this research is happening
-
Xavier University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Kundu, Anup Kumer — Xavier University of Louisiana
- Study coordinator: Kundu, Anup Kumer
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.